Illumina, Inc.
Price Chart
Financials
※ FY = Fiscal Year
Investment Metrics(as of 2026-06-18)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | $24.49B |
| Revenue | $4.39B |
| Net Income | $853M |
| Total Assets | $6.56B |
| Net Assets | $2.68B |
| Employees | 8,600 |
| Value | |
| P/E | 28.71x |
| P/B | 9.15x |
| PEG | 12.54x |
| P/S | 5.58x |
| EV/EBITDA | 21.32x |
| FCF Yield | 4.04% |
| Profitability | |
| ROE | 31.88% |
| ROA | 13.01% |
| Op. Margin | 21.45% |
| Revenue Growth | 4.80% |
| Earnings Growth | 2.29% |
| Financial Health | |
| Debt Ratio | 145.10% |
| Total Debt | $2.46B |
| FCF | $989M |
| Cash | $1.09B |
| Current Ratio | 1.75x |
| Net Debt/EBITDA | 1.13x |
| Performance | |
| 1Y Return | 79.32% |
| 1M Return | 14.24% |
| From 52W High | -8.67% |
| 1Y MDD | -25.66% |
| Trading | |
| Volume | 973,551 shares |
| Trading Value | $157M |
| Per Share | |
| EPS | $5.56 |
| BPS | $17.80 |
Company Info
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.